Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Ad-np1

Phase 1

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[2][1]

Indication

Maximum Tolerated DoseActive, not recruiting

Maximum Tolerated DosePhase 1

Active, not recruiting

Timeline

Expected Milestones

Q2 2028

Phase 1Active, not recruiting

Maximum Tolerated Dose

NCT07762001

Clinical

Trials by Indication[1]

Maximum Tolerated Dose1 trial

A Phase 1 Single-blind, Placebo-controlled, Dose Escalation Study to Evaluate the Safety of AD-NP1, a Humanized Monoclonal Antibody Targeting Human ENPP1

Active, not recruiting·AArjun Deb, MD·Phase 1·NCT07762001·36 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Ad-np1. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Ad-np1. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Arjun Deb, MD company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 1[1]
Company: AArjun Deb, MD

Related News